Sales & Earnings In Brief

This article was originally published in The Tan Sheet

04 Feb 2013
News

Executive Summary

Merck sees Oxytrol OTC as cushion against Rx patent expirations; Pfizer acquisitions boost consumer sales 16% in Q4; Latin America stands out for Mead Johnson.

Already Registered? Sign in to continue reading.

New to Pink Sheet? Start a free trial today!

Table
View full table

Topics

United States

Asia Pacific

China

Related Companies

ASK THE ANALYST
Email

Print
Bookmark
Share

Tags:

Consumer North America United States

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

PS106215

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

PS106215

All set! This article has been sent to my@email.address.

All fields are required. For multiple recipients, separate email addresses with a semicolon.

Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.

Sales & Earnings In Brief

News

Executive Summary

Related Content

Mead Johnson Hopes To Milk JV For Latin American Growth

Topics

Related Companies

You must sign in to use this functionality

Authentication.SignIn.HeadSignInHeader

Register

Ask The Analyst

Email Article

Sign In To Set a Search Alert